苏黄止咳胶囊联合特布他林及孟鲁司特钠治疗慢性咳嗽变异性哮喘临床观察

目的:观察苏黄止咳胶囊联合特布他林及孟鲁司特钠治疗慢性咳嗽变异性哮喘(CVA)的临床疗效。方法:60例按随机数字表法分为治疗组和对照组各30例,两组均给予特布他林雾化及孟鲁司特钠片口服,治疗组加服苏黄止咳胶囊。结果:治疗后治疗组hs-CRP、 EOS均低于对照组(P<0.05),治疗后治疗组咳嗽缓解时间短于对照组(P<0.05),总有效率治疗组高于对照组(P<0.05),两组不良事件发生率比较差异无统计学意义(P>0.05)。结论:苏黄止咳胶囊联合孟鲁司特钠及特布他林治疗CVA疗效较好,可更快的改善血液炎症指标、咳嗽症状,同时不增加不良事件发生率。

Objective:To observe the clinical efficacy of Suhuang Zhike Capsule combined with terbutaline and montelukast in the treatment of chronic cough variant asthma(CVA).Methods:Sixty patients were randomly divided into a treatment group and a control group,with 30 patients in each group.Both groups received nebulized terbutaline and oral montelukast,while the treatment group additionally received Suhuang Zhike Capsule.Results:After treatment,the levels of high-sensitivity C-reactive protein(hs-CRP)and eosinophil(EOS)were lower in the treatment group than in the control group(P<0.05).The time for cough relief was shorter in the treatment group(P<0.05).The total effective rate was higher in the treatment group than the control group(P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion:The combination of Suhuang Zhike Capsule,montelukast,and terbutaline is effective in treating CVA,with faster improvement in blood inflammatory markers and cough symptoms,without increasing the incidence of adverse events.